Rituximab for Early‐Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease
M. Olszewska, E. Mężyk, M. Kurbiel, W. Kmiecik, D. Turowska-Heydel, M. Sobczyk, Z. Żuber · 2025
Read Rituximab for Early‐Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease by M. Olszewska, E. Mężyk, M. Kurbiel, W. Kmiecik, D. Turowska-Heydel, M. Sobczyk, Z. Żuber (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12752856.txt.
Description
Olszewska and colleagues report a three-year-old girl whose juvenile dermatomyositis came with interstitial lung disease. Rituximab treated her with success. The disease is the most common inflammatory myopathy in children. Its lung harm can cause major disability and death. The girl had four months of muscle weakness and rash, major skin involvement, and low strength on admission.
Tests showed mild anemia, high lactate dehydrogenase, and an antibody linked to the disease. Whole-body MRI confirmed the typical muscle signs. Chest imaging showed interstitial lung disease in a nonspecific interstitial pneumonia pattern, in about a third of lung volume. Care joined steroid pulses, intravenous immunoglobulins, and methotrexate. The case was severe, so rituximab was added early. She tolerated it well. At follow-up, her strength was normal, and skin and lung signs had receded.
Catalog record
| CREATOR | M. Olszewska, E. Mężyk, M. Kurbiel, W. Kmiecik, D. Turowska-Heydel, M. Sobczyk, Z. Żuber |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |